OBS Medical

Carmel, Indiana, March 25, 2009 – OBS Medical has entered into an agreement with Beazley, a major Lloyd’s of London-based insurer of medical malpractice for US hospitals, for Beazley to provide insurance coverage at a reduced cost to hospitals that implement OBS’s Visensia® patient monitoring technology to provide early warning of clinical crises.

Recognized by Frost and Sullivan as a 2008 North American Technology Innovation award winner, OBS Medical’s Visensia hospital patient safety suite fuses data from multiple vital signs into a numerical index of a patient’s wellness. When the predictive index reaches or surpasses a set threshold, an alert is triggered, indicating a patient may be at greater risk of deterioration.

Hospitals that use Visensia in a manner approved by Beazley’s underwriters will be entitled to receive reimbursement of a portion of the premium paid for their medical malpractice insurance at the end of the policy period.  The value of this return premium will vary, depending on the coverage provided.  Return premiums of more than $100,000 have already been paid out to individual Beazley clients that have implemented agreed measures to improve the quality of patient care.

Beazley’s Lloyd’s syndicates, rated A by A.M. Best, insure US hospitals on a non-admitted or surplus lines basis and coverage can only be arranged through an accredited surplus lines broker.

OBS Medical’s Chief Operating Officer Wayne Nethercutt said, “Clinical data have demonstrated the value of Visensia in providing early warning of potentially fatal deteriorations in patients’ condition that might otherwise be missed. I am delighted that Beazley, a major insurer of hospitals’ medical malpractice exposures with a track record of innovation, has recognized the benefits this can bring in reducing med mal claims.”

About Beazley Group

Beazley Group plc (BEZ.L) is the London-based parent company of global, specialist insurance businesses with operations in the UK, US, France, Germany, Singapore, Hong Kong and Australia. Beazley manages four Lloyd’s syndicates: Syndicates 2623 and 623 underwrite a broad range of insurance and reinsurance business worldwide; Syndicate 3623 focuses on accident and health business; and 3622 is a dedicated life syndicate. In 2008, Beazley underwrote gross premiums of £875.7 million. All Lloyd’s syndicates are rated A by A.M. Best. In the US, our underwriters focus on writing specialist insurance products in the admitted market, backed by Beazley Insurance Company, Inc., an admitted property/casualty carrier in all 50 states; and surplus lines risks, backed by the Beazley syndicates at Lloyd’s. Beazley Insurance Company, Inc. is rated A by A.M. Best.

We are market leaders in many of our chosen lines, which include professional indemnity, property, marine, reinsurance, accident and life, and political risks and contingency business.

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

info@obsmedical.com

Grand Rapids, Michigan – Feb. 19, 2009 – Saint Mary’s Health Care, a member organization of Trinity Health, has completed its new Hauenstein Center facility and celebrated with several Grand Opening events, including a Community Open House on Sunday, February 15. The Hauenstein Center is a comprehensive neuroscience center with a new Emergency and Trauma Center and two floors of private critical care inpatient rooms. In this state-of-the-art facility, Saint Mary’s staff selected OBS Medical’s Visensia® patient safety suite to support its patient care operations. Together, the Hauenstein Center staff and OBS Medical are pioneering a breakthrough innovation benefiting patients and clinicians alike.

Frost & Sullivan recognized OBS Medical with the 2008 North American Frost & Sullivan Technology Innovation Award for its cutting edge Visensia® hospital patient safety suite. Visensia’s automated early warning technology fuses up to five vital signs – heart rate, respiration rate, body temperature, oxygen saturation and blood pressure – into a predictive, numerical index. The Visensia Index is an indication of a patient’s wellness and can enable significant improvement in clinical outcomes and optimization of hospital resource utilization. When the Index reaches and/or surpasses the default threshold, a Visensia Alert is triggered.

Visensia technology has been used as a tool to improve patient care and safety at Saint Mary’s since 2006. This innovative and proactive approach to patient care will be used with each of the 32 beds in the Hauenstein Center critical care unit. “We expect our critical care unit to still be state-of-the-art twenty years from now. Visensia will help us ‘red flag’ patients at risk for deterioration, so we can intervene earlier and prevent crises,” comments Clinical Nurse Specialist Lisbeth Votruba, RN.

“We are thrilled that Saint Mary’s has found continued value in Visensia and will be using it in the Hauenstein Center. They understand that in today’s challenging healthcare environment, hospitals must maximize patient safety and optimize clinical resources. The Visensia technology may be used as a resource management tool to ensure the optimal level of care is given to those who need it most,” says Frank Cheng, President and CEO of OBS Medical.

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

info@obsmedical.com

Washington, DC – January 12, 2009 – At CBI’s 3rd Annual Cardiac Safety Summit, Spaulding Clinical and OBS Medical announced that they have entered into a strategic relationship to promote an integrated suite of technologies and services for improving cardiac safety.

The non-exclusive partnership between OBS Medical and Spaulding Clinical will provide comprehensive cardiac safety services including patient recruitment, ECG/Holter data collection, in-depth cardiac safety analysis (high-throughput with cardiologist involvement), and expert cardiologist interpretation and summary.  This joint offering is positioned to be the industry’s premier cardiac safety service, as measured by data quality, breadth and depth of analysis, project completion time, and cost efficiency.

Spaulding Clinical is a Phase I clinical trial facility with comprehensive and leading-edge services.  With the most advanced technology, its integration of monitoring, recording, analyzing and reporting are all in one place. A unique specialization in cardiac safety testing for new drugs in development, Spaulding Clinical provides the highest quality results with the most accurate data and the most efficient procedures in the industry.

“We are delighted to select OBS Medical’s BioQT™ cardiac safety analytical platform for inclusion into our comprehensive Phase I services,” commented Randy Spaulding, Spaulding Clinical CEO.  “BioQT is built upon a strong scientific foundation, clinically validated with strong results and positioned to assist more pharmaceutical sponsors in their drugs’ cardiac safety analysis.  Spaulding Clinical is excited to enter into this partnership with OBS Medical so together we can offer the best cardiac safety services.”

OBS Medical provides innovative clinical algorithms such as BioQT, an advanced signal processing technique.  BioQT generates an efficient and accurate measurement of ECG QT interval, T wave morphology and other cardiac safety parameters assessed during drug trials.  It is a thorough and efficient way to produce accurate cardiac safety profiles for new and existing drugs.  OBS Medical recently conducted an industry-first cardiac safety study in which BioQT high-throughput analytical platform was used to prospectively analyze QT and T wave morphology changes for a drug compound.  BioQT data was among the information used by the FDA to allow the drug to move into its next phase of development.

“OBS Medical is thrilled about our partnership with Spaulding Clinical – together we will offer next generation technologies and services for improving cardiac safety,” commented Frank Cheng, OBS Medical CEO.  “Spaulding Clinical’s facilities are state-of-the-art, and its commitment to the highest service quality and standards and passionate pursuit of ingenious solutions will save time and money for pharmaceutical clients.”

About Spaulding Clinical

Spaulding Clinical is a 48 telemetry bed facility in West Bend, WI specializing in cardiac safety testing.  Spaulding Clinical offers a range of services including first-in-human studies, bioavailability and bioequivalence, data collection and management, definitive QTc, and Pharmacokinetics and Pharmacodynamics. Spaulding Clinical also offers ECG Core Lab and Over-reading services with state-of-the-art technology and cardiac expertise.

Contact:

Spaulding Clinical
Amanda Baltz
262.306.3324
amanda.baltz@spauldingclinical.com

Spaulding Clinical
525 S. Silverbrook Drive
West Bend, WI 53095
USA
www.spauldingclinical.com

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

OBS Medical

info@obsmedical.com

Vodafone Ventures Ltd, the corporate venture capital arm of Vodafone Group, has made an undisclosed investment in t+ Medical, the leading provider of mobile phone based technology used to transfer patient biometric data.

The t+ technology is currently used for the management of long-term health conditions and helps thousands of people in the UK manage their conditions each year.

The additional funding from Vodafone Ventures will enable t+ Medical to accelerate the roll-out of its mPRO™ (mobile patient reported outcomes) platform which has been specially designed for use in clinical trials.

The mPRO™ platform offers a number of clear benefits:

• speed new drugs to market by reducing the all important timelines between drug
• discovery and launch
• help increase patient safety by eliminating the inaccuracies caused by subjects
• not completing their paper diaries
• help pharmaceutical companies move towards a technological system of patient
• data capture as recommended by the FDA
• real-time analysis of clinical data enabling early adaptations to trials
• familiar mobile phone hardware delivers high levels of compliance among users

The technology enables the easy collection of patient data in clinical trials via a mobile device. Data is entered by subjects into an interactive diary programme on their mobile. Using secure mobile networks, the information is automatically and instantly downloaded to t+ servers where it can be analysed, ensuring any significance in the results is identified at the earliest possible opportunity.

Tim Clover, CEO of t+ Medical said: “The provision of healthcare services and clinical trials through mobile technology offers a scalable platform to allow large volumes of patient data to be securely transferred and analysed in real-time. This investment from Vodafone Ventures will help us to further drive the roll out of remote patient management solutions, to offer cost savings and improved clinical outcomes to customers around the world.”

Peters Suh, President of Vodafone Ventures said: “This investment will help to ensure that t+ Medical is able to deliver on its potential while bringing greater scale to the mHealth market.”

t+ Clinical’s mPRO (mobile patient reported outcomes) solution is short-listed for the Good Clinical Practice Journal Awards 2008.

The mPRO solution runs over the world’s largest data infrastructure, operates on mobile phones in every geography and delivers familiar, high compliance technology to study subjects worldwide. Using a unique yet practical method of gathering electronic patient recorded data through mobile phones, t+ Clinical are able to offer fast rollout within days of a finalised study, combined with real time analysis of primary outcomes.

The annual Good Clinical Practice Journal Awards are designed to recognise the remarkable achievements of individuals and organisations working in the clinical trial industry. t+ Clinical are short-listed under ‘Best technological development in clinical trials’ and in this category judges are looking for the product that represents the best advance in supporting clinical trial management.

“Outstanding. Exemplary. Impressive.” These are just some of the comments received from the judges about this years GCPj entries. Proving once again that the clinical trials sector is buzzing with innovation and a continued commitment to improving trial processes.

About t+ Clinical: established in 2007 as a subsidiary to t+ Medical Holdings, to offer data capture solutions to pharmaceutical customers for late stage clinical trials. The vision of t+ Clinical is to enable the drug discovery process to move as quickly and accurately as possible through mobile phone based, late stage clinical trials. By ensuring that every stage of data collection and analysis is as efficient as possible, high standard results are delivered in the shortest time.

For further information please e mail info@tplusclinical.com or call  +44 (0) 1235 432050

www.tplusclinical.com

www.gcpjawards.com

More than 2,000 extra students will have the chance to take doctorates in science and engineering under a £250 million scheme to tackle the technological challenges facing Britain.

The initiative, announced yesterday by Lord Drayson, the Science and Innovation Minister, will create 44 PhD training centres in the biggest expansion of postgraduate science education.

Read more.

MOUNTAIN VIEW, Calif. – November 17, 2008 – Frost & Sullivan, the Growth Partnership Company, honored healthcare companies for demonstrating leadership and innovation Wednesday, November 12, 2008 at the Excellence in Healthcare Awards Banquet held in San Antonio, Texas.

Read more.

MOUNTAIN VIEW, Calif. – November 17, 2008 – Based on its recent analysis of the central stations patient monitoring market, Frost & Sullivan recognizes OBS Medical with the 2008 North American Frost & Sullivan Technology Innovation Award for its cutting edge Visensia® Hospital Patient Safety Suite. Instead of monitoring single parameter deviations as traditional devices do, Visensia® utilizes revolutionary technology which integrates the clinical values of five vital sign parameters (heart rate, blood pressure, SpO2, skin temperature, and respiratory rate) into a more meaningful and insightful parameter, expressed as a numerical index (the Visensia® Index). This Index represents the patient’s wellness in real-time.

Faster emergency response times have improved patient outcomes, as well as reduced operational costs and expensive re-admissions. This has caused the patient monitoring industry to focus on innovations in connectivity and monitoring intelligence. While most new solutions are developed on the same basic and similar platforms, OBS Medical has broken new ground with its innovative approach to vital sign interpretation. Its safety suite not only helps detect abnormalities earlier but also nearly eliminates false-positives produced by individual vital sign monitoring.

“Unlike the traditional monitoring algorithms, the Visensia® is not a one-size-fits-all application; it personalizes patient monitoring by evaluating the ‘normal’ thresholds for individual patients the and Visensia® Index against pre-measured normal thresholds,” says Frost & Sullivan Research Analyst Mike Arani. “The addition of this innovative solution to any monitored unit will greatly boost alarm integrity and timeliness.”

Alarming facilitates centralized monitoring by alerting clinicians to the patients that require immediate care. Low alarm integrity could compromise clinical workflow and efficiency. Therefore, hospitals seek monitoring solutions that can enhance alarm accuracy and confidence in critical care applications.

There has been a growing trend in patient monitoring alerting systems to implement “secondary” alarm notifications generated at the central stations. These alarms are based on preconfigured algorithms, wherein an alert is sent to the rapid response team (RRT) when the alarm conditions are met.

Clinical trials of the Visensia® suite have proven that approximately 95 percent of the alerts generated by Visensia® were true. Moreover, Visensia Alert has detected 100 percent of severe clinical deterioration (requiring MET/RRT call) with a mean advanced warning of 6.3 hours.

“The Visensia® Hospital Patient Safety Suite can be integrated with any patient monitoring solution in the market,” notes Arani. “It can collect and analyze all five vital parameters from conventional bedside or telemetry monitors, thus enhancing the hospital’s existing monitoring system without the need for costly upgrades.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated technological innovation within its industry. This Award recognizes the ability of the company to successfully develop and introduce new/disruptive technology, formulate a well-designed product family, and make significant technology contributions to the industry.

Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

www.obsmedical.com

About Frost & Sullivan

Frost &Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company’s TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnership Services, visit www.awards.frost.com

Contact:
Jake Wengroff
210.247.3806
jake.wengroff@frost.com

Carmel, Indiana – October 7, 2008 – OBS Medical announced today the successful completion of a cardiac safety analysis in support of a pharmaceutical sponsor’s prospective drug study.

BioQT® is an advanced signal processing technique developed by OBS Medical. It provides efficient and accurate measurement of ECG QT interval, T wave morphology and other cardiac safety parameters assessed in drug trials. BioQT® is a thorough and efficient way to produce accurate cardiac safety profiles for new and existing drugs.

The recently completed BioQT-enabled cardiac safety analysis was conducted on Holter ECG data to assess the investigational drug’s effects on cardiac repolarization in normal volunteers who were randomized to drug or placebo. OBS Medical analyzed over 5 million individual heart beats, using both fully automated and semi-automated processing (the latter includes cardiologist oversight). BioQT’s comprehensive outputs include QT interval assessment, T wave morphology assessment, benchmarking analysis (drug vs. placebo, drug vs. positive control), and a cardiologist’s interpretation.

OBS Medical believes that this study may be the industry’s first in which a high-throughput analytical platform was used prospectively to analyze QT and T wave morphology changes of a drug compound under active FDA review. BioQT data was among the information FDA used to allow the drug to move into its next phase of development.

“We believe that BioQT results from definitive QT studies can be submitted to FDA in lieu of conventional ECG data, so long as an active control is included,” commented Dr. Jay Mason, a renowned and respected cardiac safety expert and Chief Medical Officer for OBS Medical. “BioQT has the capability to analyze a much greater quantity of electrocardiographic data in each subject as compared to conventional methods of analysis. The result is much greater specificity and sensitivity for abnormal repolarization, and this allows drugs to be evaluated more accurately, with fewer subjects exposed, in smaller, less expensive trials. In addition, T wave morphological analysis adds insight into the clinical significance of drug-related QT prolongation.”

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

OBS Medical
Meredith Formsma
1-866-424-6744
meredith.formsma@obsmedical.com
www.obsmedical.com

OBS Medical
11495 N Pennsylvania St., Ste 250
Carmel, IN 46032
USA

Welcome by Frank Cheng, CEO of OBS Medical

Indianapolis, Indiana – (BUSINESS WIRE, September 18, 2008) – OBS Medical hosted its first-ever Visensia® Summit on September 8. It welcomed key leaders in patient safety to its hometown of Indianapolis. Nurses, physicians and administrators that use and/or support Visensia had the opportunity to meet and learn from each other’s experiences while actively participating in its exciting growth.

Formerly known as BioSign, Visensia fuses up to five vital signs – heart rate, respiration rate, body temperature, oxygen saturation and blood pressure – into a numerical index, the Visensia Index. This Index is an indication of a patient’s wellness and enables significant improvement in clinical outcome and optimization of hospital resource utilization.

The day began with a welcome by CEO Frank Cheng and was followed by Clarian Health CEO & President Daniel F. Evans, Jr. who spoke about patient safety challenges and opportunities. The keynote speaker was Dr. Michael R. Pinsky, professor and vice chairman of Academic Affairs in the Department of Critical Care Medicine at the University of Pittsburgh Medical Center (UPMC). He presented on “Rapid Response Systems and the Use of Electronic Integrated Monitoring” and shared findings from a large UPMC study and peer-reviewed paper published in Archives of Internal Medicine – “Defining the Incidence of Cardiorespiratory Instability in Patients in Step-down Units Using an Electronic Integrated Monitoring System”. Involving 1,000 patients (18,248 hours of continuous monitoring in Phase I), the study became the largest ever continuous monitoring study for cardiorespiratory variables in non-ICU patients. This new evidence strongly supports Visensia’s ability to detect clinical instability early and thereby avert a clinical crisis.

Clarian Health - CEO Daniel F. Evans, Jr. "Patient Safety Challenges and Opportunities"

The nurses’ round table was hosted by Lisbeth Vortuba, RN, MSN of St. Mary’s Health Care, Marilyn Hravnak, RN, PhD and Leslie Edwards, BSN, CMSRN both from UPMC. The discussion focused on workflow and implementation. Additional user feedback, best practices and anecdotes were also shared. OBS Medical provided insight into future research and development, feature expansions, and implementation opportunities.

Summit attendees were from Clarian Health, University of Pittsburgh Medical Center, Saint Mary’s Health Care, Saint Joseph Mercy Oakland, Parkview Health, Bloomington Hospital, Community Health Network, Allegheny General Hospital, Saint Joseph’s, Brigham and Women’s Hospital and Borgess Health.

About OBS Medical

OBS Medical is based in Carmel, Indiana and provides innovative clinical algorithms for safer hospitals, safer patients and safer drugs. Based on intelligent algorithms such as neural networks, data fusion and ECG waveform recognition, OBS Medical technologies cover a range of medical applications including automated early crisis warning (Visensia®), automated assessment of ECG waveforms including QT interval measurement and morphology tracking (BioQT™), and EEG analysis for brain-state assessment. OBS Medical is a wholly-owned subsidiary of Oxford BioSignals Ltd. based in Oxford, UK, which was originally spun out from Oxford University.

Contact:

OBS Medical
Meredith Formsma
1-866-424-6744
meredith.formsma@obsmedical.com
www.obsmedical.com

OBS Medical
11495 N Pennsylvania St., Ste 250
Carmel, IN 46032
USA